NCT00154063已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 206
- 试验地点
- 2
- 主要终点
- Change From Baseline in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF)
研究概览
简要总结
This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of any race, 18 to 65 years of age inclusive.
- •Patients with a history of migraine (with or without aura) according to the Headache Classification Committee of the IHS. Migraine attacks have to have had an onset before age 50 and have to have been present for at least 12 months.
- •Patients with 4-12 qualified migraine attacks per month over the past three months prior to Screening, as well as during the four weeks of the Baseline Phase will be eligible for entry into this study. The interval between two qualified migraine attacks should be at least 24 hours to be counted as distinct migraine attacks. A qualified migraine attack without aura is defined as a headache that lasts 4-72 hours (if untreated or unsuccessfully treated) or if successfully treated (revised per Amendment 01). This attack has at least two of the following characteristics: unilateral location, pulsating quality, moderate or severe intensity that inhibits or prohibits daily activities or aggravation by routine physical activities such as walking up stairs. In addition, at least one of the following symptoms must be present during the headache: nausea, vomiting, or photophobia and phonophobia (revised per Amendments 01 and 02). A qualified migraine attack with aura must fulfill the same criteria as the headache attack, plus have an associated aura as defined by the Migraine Criteria of the Headache Classification Committee of the International Headache Society. An aura alone that requires acute migraine treatment will also be considered a migraine attack.
- •Male and female patients will be eligible for enrollment. Females should be either of non-childbearing potential by reason of surgery, radiation, menopause (one year post onset), or of childbearing potential and practicing a medically acceptable method of contraception (eg, abstinence, a barrier method plus spermicide, or IUD) for at least one month before study randomization and for two months after the end of the study, and have a negative serum B-hCG at Screening. Pregnant and/or lactating females are excluded. Those women using hormonal contraceptives must also be using an additional approved method of contraception (eg, a barrier method plus spermicide, or IUD) starting with the Baseline Phase and continuing throughout the entire study period.
- •Patients with a Body Mass Index (BMI) between 19 to 40 kg/m2 inclusive at Screening.
- •Patients who are willing to participate and have provided written informed consent prior to being exposed to any study-related procedures.
排除标准
- •Patients with chronic daily headaches as defined by more than 14 headache days per month on average during the three months prior to Screening,
- •Patients with cluster headaches and other trigeminal autonomic cephalalgias, and other primary headaches (except tension-type headache) and secondary headaches (defined according to the Headache Classification Committee of the IHS 2004),
- •Patients with a history of being non-responsive to more than two classes of adequately conducted, prophylactic migraine treatments (e.g., beta blockers, calcium channel blockers, tricyclics, MAOIs, valproate (divalproex), topiramate, gabapentin),
- •Patients who use the following medications as described:
- •Use of marketed triptans for 10 days or greater per month on average,
- •Use of ergot-containing medications for ten days or greater per month on average,
- •Use of NSAIDs, acetaminophen, or isometheptene-containing agents for 15 days or greater per month on average,
- •Use of opioids for 10 days or greater per month on average,
- •Use of any two or more of the above medications for 15 days or greater per month on average,
- •Patients with clinically significant neurological illness, other than migraine, that, in the opinion of the Investigators, may have the potential of altering pain perception or reporting,
- •Patients with a history of or currently having major psychiatric disorders including schizophrenia, major depressive disorder, or bipolar disorder,
- •Patients who are known to be positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, or human immunodeficiency virus (HIV),
- •Patients with elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) >= 1.5 times the upper limit of normal (ULN),
- •Patients with evidence of significant active hematological disease; white blood cell count cannot be less than or equal to 2500/uL or an absolute neutrophil count less than or equal to 1000/uL,
- •Patients with clinically significant ECG abnormality, including prolonged QTc (Fridericia correction) defined as >= 450 msec for males and >= 470 msec for females,
- •Patients with clinically significant active hepatic disease, cardiovascular, metabolic, respiratory, renal, endocrinological, gastrointestinal diseases, and bacterial or viral infections within 30 days prior to Screening or during the Baseline Phase,
- •Patients with known or suspected history of alcoholism or drug abuse within the previous two years, or a positive finding on urinary drug screening of other than prescribed medications,
- •Patients who have had severe allergic reactions to multiple drugs,
- •Patients with any other condition that would make them, in the opinion of the PI, unsuitable for this study,
- •Patients that have participated in a study involving administration of an investigational compound (including E2007) within one month of Visit 1 (Screening),
- •Patients with a known or suspected allergy to lactose, excluding lactose intolerance,
- •Patients who use the following medications for any medical reason during the study: beta-blockers, tricyclic antidepressants, antiepileptics, calcium channel blockers, monoamine oxidase inhibitors, NSAIDs daily, magnesium supplements at high doses (ie, 600 mg/day), riboflavin at high doses (ie, 100 mg/day), corticosteroids, local anesthetics, botuliunum toxin, or herbal preparations such as feverfew or St. John's Wort. Patients who use non-pharmacological prophylactic approaches that were started at least one month prior to Screening may be continued throughout the study.
- •(revised per Amendment 03)
- •Patients who fail to complete the migraine diary adequately during the Baseline Phase (ie, patients, who do not have complete diary entries for at least 21 days of the Baseline Phase).
- •Randomized patients will be both male and female, 18-65 years of age, of any race, with a history of migraine headaches (with or without aura according to the Headache Classification Committee of the International Headache Society (IHS, 2004 guideline) for at least 12 months, with an onset before age 50, experiencing 4-12 migraine attacks per month during both the 3 months prior to Screening and the Baseline Phase. Patients' Body Mass Index (BMI) should be between 19 to 40 kg/m2 inclusive at Screening.
研究组 & 干预措施
Placebo
Placebo Comparator
During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
干预措施: Placebo (Other)
E2007
Experimental
During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
干预措施: E2007 (Drug)
结局指标
主要结局
Change From Baseline in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF)
时间窗: Baseline to Week 19
A migraine period was defined as a migraine headache that started, ended, or recurred within 24 hours. If the headache persisted for longer than 24 hours, it was considered a new migraine period. Participants recorded the frequency of migraine period in diary. Efficacy analyses were performed using both the 24-hour and 48-hour rule for defining migraine periods. Data is presented as mean number of migraine period per 28 days +/- standard error. A negative change indicates a decrease in the number of migraine periods from baseline. LOCF = last observation carried forward (ie, observation from last phase with active treatment)
次要结局
- Change From Baseline in Average Migraine Severity Per Migraine Attack in Treatment Phase (LOCF)(Baseline to Week 19)
- Change From Baseline in Migraine Attack Frequency Per 28 Days in Treatment Phase (LOCF)(Baseline to Week 19)
- Change From Baseline in Number of Days With Migraine Attack Per 28 Days in Treatment Phase (LOCF)(Baseline to Week 19)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Missed Work or School(Baseline, Week 23)
- Change From Baseline in Number of Days Requiring Symptomatic Rescue Medication Per 28 Days in Treatment Phase (LOCF)(Baseline to Week 19)
- Change From Baseline in Number of Participants With Patient Global Impression of Change (PGIC) of Migraine (LOCF)(Baseline to Week 23)
- Percentage of Participants With a Greater Than or Equal to 50% Decrease in Migraine Attack Frequency Per 28 Days in Treatment Phase (LOCF)(Week 5 to Week 19)
- Change From Baseline in Average Duration Per Migraine Attack in Treatment Phase (LOCF)(Baseline to Week 19)
- Change From Baseline in Migraine Period Frequency Per 28 Days in Maintenance Phase(Baseline, Week 11 to Week 19)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Headaches(Baseline, Week 23)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Less Work or School(Baseline, Week 23)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Less Housework(Baseline, Week 23)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Missed Non-Work Activities(Baseline, Week 23)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Headache Pain Score(Baseline, Week 23)
- Change From Baseline of Migraine Disability Assessment Questionnaire Score (MIDAS) at Week 23: Missed Housework(Baseline, Week 23)
- Percentage of Participants With a Greater Than or Equal to 50% Decrease in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF)(Week 5 to Week 19)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureType 2 Diabetes MellitusHeart FailureNCT02917031AstraZeneca348
招募中
3 期
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialHypereosinophilic SyndromeNCT05334368GlaxoSmithKline109
已完成
3 期
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular DiseaseDementia, VascularNCT00165737Eisai Inc.974
进行中（未招募）
3 期
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)Hypereosinophilic SyndromeNCT04191304AstraZeneca134
终止
3 期
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinType 2 Diabetes MellitusNCT03608358AstraZeneca41